These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6410560)

  • 1. Pretreatment of isolated adult islets with antibody. Effect on survival in allogeneic hosts.
    Reece-Smith H; McShane P; Morris PJ
    Transplantation; 1983 Aug; 36(2):228-30. PubMed ID: 6410560
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of reduction of class II antigens on the survival of pancreatic allografts.
    Spillenaar-Bilgen EJ; Bouwman E; de Bruin RW; Marquet RL; Jeekel J
    Transplant Proc; 1989 Feb; 21(1 Pt 1):515-6. PubMed ID: 2495619
    [No Abstract]   [Full Text] [Related]  

  • 3. Rat pancreatic islet pretreatment with anti-MHC class II monoclonal antibodies and culture: in vitro MLIC test response does not predict islet allograft survival.
    Bretzel RG; Flesch BK; Brennenstuhl G; Greiner I; Hering BJ; Woehrle M; Federlin K
    Acta Diabetol; 1993; 30(1):49-56. PubMed ID: 8329731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment of rat pancreatic islets with MHC I-A monoclonal antibody: in-vitro and in-vivo effects on islet antigenicity.
    Flesch BK; Bretzel RG; Otto DA; Ernst-Schlegel M; Federlin K
    Horm Metab Res; 1991 Aug; 23(8):357-61. PubMed ID: 1794836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of rat islet allografts with the use of ultraviolet irradiation, without immunosuppression.
    Hardy MA; Lau H; Reemtsma K
    Transplant Proc; 1984 Jun; 16(3):865-9. PubMed ID: 6233774
    [No Abstract]   [Full Text] [Related]  

  • 6. Depletion of donor Ia+ cells before transplantation does not prolong islet allograft survival.
    Gores PF; Sutherland DE; Platt JL; Bach FH
    J Immunol; 1986 Sep; 137(5):1482-5. PubMed ID: 3091683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term metabolic and immunological considerations in transplantation of pancreatic islets.
    Ziegler MM; Reckard CR; Barker CF
    J Surg Res; 1974 Jun; 16(6):575-81. PubMed ID: 4275731
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of anti-Ia antibodies, culture, and cyclosporin on prolongation of canine islet allograft survival.
    Alejandro R; Latif Z; Noel J; Shienvold FL; Mintz DH
    Diabetes; 1987 Mar; 36(3):269-73. PubMed ID: 3100370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ganglioside (Cronassial) treatment on MHC Ia antigen expression and allograft survival of pancreatic islets in diabetic rats.
    Bretzel RG; Flesch BK; Willig J; Woehrle M; Federlin K
    Diabetologia; 1990 Feb; 33(2):112-4. PubMed ID: 2109713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies.
    Lloyd DM; Cotler SJ; Letai AG; Stuart FP; Thistlethwaite JR
    Diabetes; 1989 Jan; 38 Suppl 1():104-8. PubMed ID: 2642828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental transplantation of fetal pancreas and isolated islets in the rat: studies of donor pretreatment and recipient immunosuppression.
    Garvey JF; Millard PR; Morris PJ
    Transplant Proc; 1980 Dec; 12(4 Suppl 2):186-9. PubMed ID: 6784306
    [No Abstract]   [Full Text] [Related]  

  • 12. Histocompatibility-dependent long-term islet of Langerhans survival induced by antithymocyte globulin.
    Beyer MM; Friedman EA
    Transplant Proc; 1979 Jun; 11(2):1436-9. PubMed ID: 112739
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of individual MHC subregions (RT1.A,B,D) and treatment with anti-RT1.D monoclonal antibody on survival of pancreatic islet allograft in the rat].
    Kim E
    Nihon Geka Gakkai Zasshi; 1989 May; 90(5):736-44. PubMed ID: 2507898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial class II-positive cell depletion by donor pretreatment with gamma irradiation. Evidence of differential immunogenicity between vascularized cardiac allografts and islets.
    Stegall MD; Tezuka K; Oluwole SF; Engelstad K; Jing MX; Andrew J; Hardy MA
    Transplantation; 1990 Feb; 49(2):246-51. PubMed ID: 2137652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic properties of fetal mouse proislets.
    Simeonovic CJ; Lafferty KJ
    Transplant Proc; 1987 Feb; 19(1 Pt 2):938-9. PubMed ID: 3152643
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of cyclosporin-A, low-temperature culture, and anti-Ia antibodies on prevention of rejection of rat islet allografts.
    Terasaka R; Lacy PE; Hauptfeld V; Bucy RP; Davie JM
    Diabetes; 1986 Jan; 35(1):83-8. PubMed ID: 3079714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of class II antigen on neonatal rat islets by interferon and tumor necrosis factor: lack of correlation of expression of class II antigen and allograft rejection.
    Kover K; Moore WV
    Transplant Proc; 1990 Apr; 22(2):853-4. PubMed ID: 2109419
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental transplantation of pancreatic islet allografts.
    Schulak JA; Reckard CR
    J Surg Res; 1978 Dec; 25(6):562-71. PubMed ID: 102875
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergy of class I and class II MHC deficiency (C1D and C2D) islets and early short-term suppression in achieving long-term islet graft survival and tolerance induction.
    Pittman K; Berzina P; Contreras J; Bilbao G; Thomas F; Thomas J
    Transplant Proc; 1999; 31(1-2):635-6. PubMed ID: 10083271
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of humoral immunity in pancreatic islet allo- and xenograft rejection.
    Ahn M; Sohn C; Chang E; Chu G; DeMatteo RP; Barker CF; Markmann JF
    Transplant Proc; 1996 Apr; 28(2):840-1. PubMed ID: 8623428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.